Zecchin, Davide <br/><br/>
BRAF V600E is a determinant of sensitivity to proteasome inhibitors.  [electronic resource] 

 -  Molecular cancer therapeutics  Dec 2013 
 - 2950-61 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-13-0243  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>14-3-3 Proteins--genetics<br/>Antineoplastic Agents--pharmacology<br/>Biomarkers, Tumor--genetics<br/>Cell Line, Tumor<br/>Cluster Analysis<br/>Drug Resistance, Neoplasm--genetics<br/>Drug Screening Assays, Antitumor<br/>Exoribonucleases--genetics<br/>Female<br/>Genotype<br/>Humans<br/>Indoles--pharmacology<br/>Mutation<br/>Proteasome Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Sulfonamides--pharmacology<br/>Telomerase--genetics<br/>Xenograft Model Antitumor Assays